The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive aztreonam ...

The researchers found that 69,213,936 prescriptions for OMDs were dispensed in the United States during the study period, (HealthDay News) — Prescriptions of obesity management drugs (OMDs) have ...

Results showed 92.9% of mirikizumab-treated patients who were in clinical remission at 1 year maintained clinical remission at 2 years. Continuous treatment with mirikizumab was associated with ...

Interim findings showed, the estimated mean annualized bleeding rate for treated bleeds was 0.53, with a median ABR of 0. Topline results were announced from a phase 3 trial evaluating Mim8 in ...

HealthDay News — The US Food and Drug Administration (FDA) has approved the first-ever clinical trials testing pig kidney transplants in people with kidney failure, marking a major step forward in ...

Ozempic (semaglutide) Glucagon-like peptide-1 receptor agonist To reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, and cardiovascular death in ...

A higher risk for ischemic heart diseases was associated with IBD only in male patients, whereas a negative association was seen among female patients. HealthDay News — Male patients with ...

Elevated LDL cholesterol, total cholesterol, triglycerides linked to reduced risk for glaucoma. HealthDay News — Elevated high-density lipoprotein cholesterol (HDL-C) is associated with an ...

The 2023 match saw a significant number of unfilled programs; of 115 programs, 35 failed to fill all positions. HealthDay News — The number of anesthesiology residents applying to pain medicine ...

BR55 was safe and highly accurate (>95%) at marking VEGFR2 expression in patients with breast, ovarian and thyroid cancer, as well as Crohn disease. The Food and Drug Administration (FDA) has ...

FDA issued a safety communication regarding the potential for missed alerts with diabetes devices due to software or hardware changes; a wearable continuous apomorphine infusion device has been ...